GlassScriptPhysician profile
Sardha Perera
NPI 1114995552
$1,808.94
in general payments reported to CMS, 2019-2025
12 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $107 · 2021: $107 · 2022: $63.76 · 2023: $220 · 2024: $837 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680 · Travel and Lodging: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.65 |
| Travel and Lodging | $567.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $778.60 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $287.40 | 2020-2024 | Ztlido |
| Relievant Medsystems, INC. | $274.50 | 2019-2023 | Intracept |
| Boston Scientific Corporation | $139.99 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $132.50 | 2022-2024 | Intellis Adaptivestim |
| Medtronic USA, INC. | $84.13 | 2019-2020 | |
| Abbott Laboratories | $24.13 | 2023 | Proclaim |
| Coastal Medical Technologies LLC | $22.65 | 2023 | |
| Si-Bone, INC. | $22.55 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $21.70 | 2025 | |
| Averitas Pharma INC. | $14.93 | 2025 | Qutenza |
| Electronic Waveform Lab, INC. | $5.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sardha Perera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.